Most professionals, including plastic surgeons, seem to deliberately create bland, whitewashed communications when they market their practices. They look at what everyone else is doing or saying on websites, in newsletters, in invitations and other
The June 2011 FDA approval of LAVIV (azficel-T) for improving moderate to severe nasolabial fold wrinkles was named the No. 3 top story of 2011 in cell and gene therapy and regenerative medicine at the 2012 Cell & Gene Therapy Forum in Washington, D.
Close to one in four women who undergo a partial mastectomy will need a reexcision, and there is substantial variation in the rate of reexcisions by surgeons and centers that cant be explained by patients clinical characteristics, according to a stud
Staged reconstruction with fat grafting to the breast followed by implant placement may be an option for breast cancer patients who have undergone radiation therapy after all, a new study suggests.
The FDA gave its coveted nod to Roche’s Erivedge for the treatment of basal cell carcinoma.
The Vanderbilt Center for Surgical Weight Loss is developing an online education seminar for prospective patients to view in the privacy of their own homes as opposed to en masse in the hospital setting.
The FDA has cleared the Cynosures Cellulaze Workstation for commercial distribution.
To keep pace with breaking news in Europe’s ever-evolving PIP Breast Implant scandal, Plastic Surgery Practice will now provide a weekly round-up of the top PIP stories. German Gov’t: TiBREEZE Implants Must Be Removed This week, the
The third Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium will be held on July 20-22, 2012 at the Conrad New York.
As panic grips Europe in the wake of the Poly Implant Prothese (PIP) breast implant scandal, growing numbers of women are choosing to have these faulty and potentially toxic implants removed. PIP implants were manufactured with industrial silicone